Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 6/20 | 0.59 |
| ▸ | GNPAT | O15228 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.47 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.47 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.47 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.45 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16661378 | 1.00 | NOD1 (0.59) | NOD1GNPATFOLH1NAALAD2RIMKLA | |
| SCHEMBL16715886 | 1.00 | NOD1 (0.59) | NOD1GNPATFOLH1NAALAD2RIMKLA | |
| SCHEMBL25850237 | 0.98 | NOD1 (0.61) | NOD1GNPATFOLH1NAALAD2RIMKLA | |
| SCHEMBL21937168 | 0.98 | NOD1 (0.61) | NOD1GNPATFOLH1NAALAD2RIMKLA | |
| SCHEMBL25977900 | 0.98 | NOD1 (0.61) | NOD1GNPATFOLH1NAALAD2RIMKLA | |
| SCHEMBL21937004 | 0.98 | NOD1 (0.61) | NOD1GNPATFOLH1NAALAD2RIMKLA | |
| SCHEMBL21937170 | 0.98 | NOD1 (0.61) | NOD1GNPATFOLH1NAALAD2RIMKLA | |
| SCHEMBL21937167 | 0.98 | NOD1 (0.61) | NOD1GNPATFOLH1NAALAD2RIMKLA | |
| SCHEMBL25976546 | 0.98 | NOD1 (0.61) | NOD1GNPATFOLH1NAALAD2RIMKLA | |
| SCHEMBL25976528 | 0.98 | NOD1 (0.61) | NOD1GNPATFOLH1NAALAD2RIMKLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160193154-A1 | Pharmaceutical Composition for Oral Insulin Administration Comprising a Tablet Core and an Anionic Copolymer Coating | NOVO NORDISK A/S (DK) | 2016-07-07 | — | — | US | disclosed |
| US-9035020-B1 | Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids | NOVO NORDISK A/S (DK) | 2015-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160193154-A1 | Pharmaceutical Composition for Oral Insulin Administration Comprising a Tablet Core and an Anionic Copolymer Coating | IAPP, INSR, GPR119 | NOD1 1050/4885GNPAT 2105/4885FOLH1 1798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.